A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis

Inclusion Criteria: * Hospitalized patients with positive blood culture for Staphylococcus epidermidis. * Diagnosis of staphylococcal infection based on a positive culture for Staphylococcus epidermidis on 2 consecutive occasions within 12 hours. * Study medication must be started not later than 24 hours of the last qualifying positive blood culture. * Patients for whom antibiotic treatment is not clinically indicated at the start of the study. * Patients must have sufficient venous access to permit administration of study drug and monitoring of safety variables. * Patients who have hepatic and renal parameters within 2X ULN (upper level of normality) at screening. * Fecund females patients must not be pregnant (confirmed by pregnancy test at entry) and must be on appropriate mechanical (intra-uterine device) or pharmacological ("pill") contraception. * Written informed consent must be obtained before admission in the study. Exclusion Criteria: * Prior antibiotic usage: patients who have received (within 48 hours of study entry) a systemic anti-staphylococcal antibiotic for longer than 24 hours. * Concomitant antibiotic or anti-bacterial agents except as allowed by the protocol or in life-threatening complications. * Patients with devices infected with Staphylococcus epidermidis or other important pathogens, including in implants, heart valves and catheters. * Patients known to have AIDS or who are HIV-positive. * Neutropenic patients with neutrophil count below 0.5x10\^9/L. * Patients with staphylococcal endocarditis, mediastinitis, meningitis, osteomyelitis and/or joint infections, lung/pleural infections, septic shock. * Patients with methicillin-sensitive coagulase-negative staphylococcus (CNS) infections (MSSE). * Patients who have known hypersensitivity to any constituent of hLF1-11. * Patients who have received an investigational drug within three months prior to the study that may interfere with the interpretation of study results. * Patients with a concomitant medical condition, in whom, in the opinion of the Investigator, participation may create an unacceptable risk for the patient. * Patients considered inappropriate by the PI for enrolment in the study, for any reason.